# Administration of Intranasal Midazolam for Anxiety in Palliative Care

> **NCT06330584** · PHASE2 · RECRUITING · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 36 (estimated)

## Conditions studied

- Anxiety
- Acute Anxiety
- Palliative Care

## Interventions

- **DRUG:** Placebo Nasal Spray 0 mg/spray
- **DRUG:** Midazolam Nasal Spray 0.45 mg/spray
- **DRUG:** Midazolam Nasal Spray 0.9 mg/spray

## Key facts

- **NCT ID:** NCT06330584
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-20
- **Primary completion:** 2025-09
- **Final completion:** 2025-10
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06330584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06330584, "Administration of Intranasal Midazolam for Anxiety in Palliative Care". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06330584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*